# Diabetes Diagnostic Criteria: FPG, OGTT, and HbA1c Explained > ADA cut points define dysglycemia categories—not HOMA-IR and not one restaurant spike. *Published 2026-07-10 · Updated 2026-07-10 · By Marcus Chen* In short **ADA diabetes:** A1c ≥6.5%, FPG ≥126 mg/dL, 2-h 75-g OGTT ≥200 mg/dL, or random ≥200 mg/dL with classic symptoms. **Prediabetes:** A1c 5.7–6.4%, FPG 100–125, 2-h OGTT 140–199. Confirm abnormalities; treat A1c as fallible when red-cell biology is altered. These tests are not HOMA-IR. Lab printouts turn into identity labels overnight. The ADA tables are precise if you keep confirmation rules, SI units, and the difference between dysglycemia diagnosis and insulin-resistance surrogates. *This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.* ## What are the adult non-pregnant diagnostic cut points? Diabetes: HbA1c ≥6.5% (48 mmol/mol); fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) after ≥8 hours fasting; 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) on a 75-g OGTT; or random plasma glucose ≥200 mg/dL with classic hyperglycemic symptoms. Prediabetes: A1c 5.7–6.4%; impaired fasting glucose 100–125 mg/dL; impaired glucose tolerance 140–199 mg/dL at two hours. These intermediate bands are actionable for prevention programs such as Diabetes Prevention Program–style lifestyle intervention. Gestational diabetes uses separate protocols and thresholds—do not paste non-pregnant adult cutoffs into pregnancy care without the GDM algorithm. ## How do confirmation and discordance work? Unless hyperglycemia is unequivocal and symptomatic, confirm diagnosis with a second abnormal test. Two abnormal results from the same sample or two different tests both appear in Standards of Care logic. Discordance is expected: A1c and glucose tests do not always light up together. Each confirmed pathway is still valid; the job is not to pick the “nicer” number and ignore the other. Fingerstick glucometers and continuous glucose monitors are management tools; formal diagnosis typically relies on laboratory plasma glucose or A1c methods under clinical standards. Key reference points CategoryA1cFPG2-h 75-g OGTT Normal Prediabetes5.7–6.4%100–125 mg/dL140–199 mg/dL Diabetes≥6.5%≥126 mg/dL≥200 mg/dL ## When should clinicians prefer glucose tests over A1c? Altered erythrocyte lifespan, hemoglobin variants, recent transfusion, and some pregnancy or CKD contexts can distort A1c relative to true mean glucose. OGTT remains useful when fasting glucose looks fine but post-load dysglycemia is suspected—PCOS, prior GDM, strong family history—because impaired glucose tolerance is a post-challenge phenotype. Therapy targets after diagnosis (for example A1c goals on treatment) are a separate conversation from the diagnostic cut that labeled the disease. ## How does this relate to insulin resistance content? Insulin resistance can exist years before diagnostic dysglycemia. HOMA-IR, triglycerides, waist circumference, and blood pressure paint risk earlier but do not replace ADA diagnostic tables. Conversely, do not claim “I cured diabetes” because HOMA improved while A1c still meets diabetes criteria, or the reverse. Keep tools in their lanes. Sources: [ADA diabetes diagnosis](https://diabetes.org/about-diabetes/diagnosis); [Standards of Care diagnosis chapter](https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes); [CDC prediabetes A1C testing](https://www.cdc.gov/diabetes/diabetes-testing/prediabetes-a1c-test.html). Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. ## Sources 1. [ADA diabetes diagnosis](https://diabetes.org/about-diabetes/diagnosis) 2. [Standards of Care diagnosis chapter](https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes) 3. [CDC prediabetes A1C testing](https://www.cdc.gov/diabetes/diabetes-testing/prediabetes-a1c-test.html) --- Source: https://healthcanon.com/metabolic-health/diabetes-diagnostic-criteria-fpg-ogtt-hba1c Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt